UNI-BIO GROUP released its interim results, with a net profit of HKD 75.955 million, a year-on-year increase of 12.7%
I'm PortAI, I can summarize articles.
UNI-BIO GROUP released its mid-term results for 2025, with revenue of HKD 310 million, a year-on-year increase of 13.4%; net profit of HKD 75.955 million, a year-on-year increase of 12.7%; and basic earnings per share of HKD 1.27. The growth in performance is attributed to the expansion of sales channels, increased demand for BoguTai®, and market attention to already listed drugs, reflecting the group's strategic effectiveness in operational efficiency, cost control, and commercial execution
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments